The Paris Court of Appeal has refused to grant Merck Sharp & Dohme (MSD) a preliminary injunction based on a supplementary protection certificate (SPC) against French pharmaceutical company Biogaran.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
SPC, supplementary protection certificate, patent, Biogaran, Paris Court of First Instance, Merck Sharp & Dohme